Overview
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Lobbying Costs
None declared
Financial year: Apr 2022 - Mar 2023
Lobbyists (Full time equivalent)
0.75 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
4
Lobbying Costs over the years
-
Info
Cancer Research UK (CRUK)
EU Transparency Register
54970512687-47 First registered on 01 Dec 2009
Goals / Remit
Cancer Research UK is the world’s leading cancer charity, dedicated to saving and improving lives through our research, influence and information. We’re the largest charitable funder of cancer research in the world,
funding around 50% of all publicly funded cancer research in the UK. https://www.cancerresearchuk.org/sites/default/files/cruk_annual_report_accounts_2022-2023.pdf In 2022/23, we spent £415m on new and ongoing research. Our network of centres and institutes are where more than 4,000 scientists, doctors and nurses work together to help us beat cancer, carrying out everything from laboratory studies to large-scale clinical trials. Through programmes like Cancer Grand Challenges, we bring together a worldwide network of leading scientists from across the globe to carry out groundbreaking research. We also work with other research funders, cancer societies and governments around the world to pool our resources and knowledge to accelerate progress towards beating cancer.Main EU files targeted
UK-EU relations, UK Data Adequacy, Clinical Trial Regulation, Horizon Europe, tobacco control and other public health potentially including obesity in future; potentially the Orphan & Paediatric Medicines Regulations and the Pharmaceutical Regulation. EU Cancer Plan in general.
Address
Head Office
2 Redman Place
London E20 1JQ
UNITED KINGDOMEU Office
2 Redman Place
London E20 1JQ
UNITED KINGDOMWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 75% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 15 Sep 2024
Name Start date End Date Mr Mark HEFFERNAN 20 Sep 2019 19 Sep 2020 Ms Catherine CASTLEDINE 08 Aug 2015 06 Aug 2016 Mr Andrew Hollingsworth 04 Jul 2013 02 Jul 2014 Complementary Information
0.8 Full-time equivalent in the Europe & Global Affairs Manager role. Some policy development support. Occasional involvement by other staff across the organisation.
CRUK Trustee, Professor Pamela Kearns, is involved in conversations about the EU pharmaceutical legislation in her role as Past President of the European Society for Paediatric Oncology (SIOPE) e.g. https://siope.eu/media/documents/1final-programme-mac-siope-gold-sept-2023.pdf
https://www.cancerresearchuk.org/about-us/how-we-are-run/our-trusteesPerson in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Non-governmental organisations, platforms and networks and similar
-
Networking
Affiliation
We are a paying member of or work jointly with many associations/networks etc, including the Cancer Grand Challenges https://cancergrandchallenges.org/, European Organisation for Research and Treatment of Cancer (EORTC), International Cancer Benchmarking Partnership, Cancer Prevention Europe (CPE - led by IARC) European Public Health Alliance (EPHA), the Smoke Free Partnership (SFP), the Union for International Cancer Control (UICC), the Federation of European Academies of Medicine (FEAM), Association of European Cancer Leagues (ECL), the European Cancer Organisation (ECO), Global Alliance for Tobacco Control (GATC), NCD Alliance (NCDA), G7 Cancer initiative, International Cancer Research Partnership (ICRP). We would be happy to expand if needed.
Member organisations
None declared
-
Financial Data
Interests represented
Does not represent commercial interests
Closed financial year
Apr 2022 - Mar 2023
Lobbying costs for closed financial year
Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.
Total organisational budget in closed year
840,000,000€
Major funding types in closed year
Donations
Major contributions in closed year
None declared
Other financial info
For a list of benefactors, major supporters, major trusts and foundations, corporate partners and other donation information, please see CRUK's annual report and accounts https://www.cancerresearchuk.org/about-us/our-organisation/how-we-spend-your-money
In 2022/23, our income was a total of £718.8 million (840 million EUR using exchange rate on 5 February 2024 xe.com). In 2022/23, our annual expenditure was £641m (749 million EUR). This includes:
• £398m committed to research
• £27m on information and influencing work
• £109m raising donated income and managing our investments
• £107m running our shops and other trading activity.
In 2022/23, we spent £415m on new and ongoing research. This includes:
£176m on research projects focused on specific cancer types
£89m relevant to all types of cancer (eg research infrastructure and research studies looking at cancer survivorship)
£83m on basic research understanding the fundamental biology of cancer
£40m on research admin and support costs (eg peer review, grant management, IT and other support costs)
£27m on revenue shares (share of royalties from sales of innovations developed from our research, which we passed on to others)
In 2022/23, we spent £18.7m on research specific to cancers that affect 0–24-year-olds, making us the UK's biggest charitable funder of research into children’s and young people’s cancers.
For more information please see:
https://www.cancerresearchuk.org/about-us/our-organisation/how-we-spend-your-money
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
Cancer
Communication activities
Attend events aimed at the cancer, health and science policy communities at which EU officials can be present (e.g. European Health Forum Gastein, 2023). Participation in EU-facing coalition/org meetings and activities at which EU officials can be present (e.g. the European Cancer Organisation's European Cancer Summit 2023). In the past, CRUK has held a meetings programme including EU officials and elected politicians, and we intend to do so again in future, as appropriate to the UK's new relationship with the EU. Potentially CRUK/joint articles for European media.
Other activities
None declared
Meetings
Meetings
4 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 14 Mar 2024 Location online Subject Meeting with Cancer Research UK Cabinet Cabinet of Commissioner Stella Kyriakides Attending - Tove Ernst (Cabinet member)
- Stella Kyriakides (Commissioner)
-
Date 03 Mar 2020 Location Brussels Subject Horizon Europe - Mission on Cancer Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Maria Koleva (Cabinet member)
-
Date 03 Mar 2020 Location Brussels Subject Horizon Europe - Mission on Cancer Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Maria Koleva (Cabinet member)
-
Date 07 Mar 2018 Location Brussels Subject Impact of Brexit on cancer research Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Annika Nowak (Cabinet member)